RecruitingPhase 2ACTRN12607000633482

Global Prevention of Asthma in Children Study

A Phase II Multicenter, Controlled, Double-Blind Study Using Immunoprophylaxis in the Primary Prevention of Allergic Disease


Sponsor

National Institute of Allergy and Infectious Diseases

Enrollment

200 participants

Start Date

Jun 1, 2006

Study Type

Interventional

Conditions


Eligibility

Sex: Both males and femalesMin Age: 12 MonthssMax Age: 30 Monthss

Plain Language Summary

Simplified for easier understanding

This study is looking at whether a probiotic treatment — a mixture of healthy bacteria given by mouth — can help prevent asthma from developing in young children who have eczema and food allergies. These children are at higher risk of going on to develop asthma. The probiotic is designed to be taken daily and may help train the immune system in a way that reduces the chance of developing airway problems later on. You may be eligible if: - Your child is between 12 and 30 months of age - Your child has been diagnosed with eczema (atopic dermatitis) - There is a family history of eczema, allergic rhinitis, or asthma - Your child has a known allergy to egg white, cow's milk, peanut, or soybean - Your child weighs at least 8 kg - You are willing to provide informed consent You may NOT be eligible if: - Your child has a known allergy to house dust mite, cat, or grass pollen - Your child was born before 36 weeks of pregnancy - Your child has previously been diagnosed with asthma OR had 3 or more wheezing episodes in the first year of life - Your child has a chronic lung disease - Your child has received immunotherapy or immunosuppressive medications Talk to your doctor about whether this trial might be right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

House Dust Mites - 7.5 mcg/0.2ml (Dermatophagoides pteronyssinus & Dermatophagoides farinae); Cat (11.3 mcg/0.2ml) and Timothy Grass (15.0 mcg/0.2ml) or matching placebo orally once daily for 12 month

House Dust Mites - 7.5 mcg/0.2ml (Dermatophagoides pteronyssinus & Dermatophagoides farinae); Cat (11.3 mcg/0.2ml) and Timothy Grass (15.0 mcg/0.2ml) or matching placebo orally once daily for 12 months


Locations(3)

New York, United States of America

Berlin, Germany

Stockholm, Sweden

View Full Details on ANZCTR

For the most up-to-date information, visit the official listing.

Visit

ACTRN12607000633482


Related Trials